OncoMatch/Clinical Trials/NCT07817147
CREO - Microwave Ablation Feasibility Study
Official title: Investigator-Initiated Feasibility Study of a Novel Endoscopic Ultrasound Guided Microwave Ablation Device in Patients With Locally Advanced, Unresectable, or Metastatic Cancer
Is NCT07817147 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies EUS-Guided MWA Device for pancreatic cancer.
Treatment: EUS-Guided MWA Device — The goal of this study is to assess the overall success of energy delivery during treatment using the ultrasound guided microwave ablation device in patients with locally advanced, unresectable, or metastatic cancer. Secondly, this study aims to explore the procedural/clinical safety of treatment with the device and the antitumor effect following treatment with the device.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center and Gateway Hospital · Gilbert, Arizona
- Cedars Sinai · Los Angeles, California
- Rush University Medical Center · Chicago, Illinois
- Mayo Clinic Rochester · Rochester, Minnesota
- University of Tennessee Medical · Knoxville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07817147 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify